Check SCREEN READER MODE to make this survey compatible with screen readers.
S100 co-payment Initiative survey for Hepatitis B
Introduction
Hepatitis NSW invites you to participate in this survey to share your experiences as a person living with hepatitis B who participates in section 100 high specialised drugs program for hepatitis B medicines, in NSW.
The Highly Specialised Drugs (HSD) Program provides access to specialised Pharmaceutical Benefits Scheme (PBS) medicines for the treatment of chronic conditions. NSW government reimburses community pharmacies the co-payment for the hepatitis B medicines Entecavir (Baraclude), Tenofovir (Viread) so you do not get charged.
The survey is anonymous, and data de-identified. Aggregate data will be shared with NSW Health and Service NSW to inform a project by NSW Health to understand the best way to administer this initiative in the future. There will be no changes to eligibility for your medicines or for the co-payment initiative.
Please answer all questions before Thursday the 12th November 2020.